Journals / Journal of Clinical and Analytical Medicine / 2014 / Cilt: 5 - Sayı: 3

Güvenirlik ve Kullanım Açısından Yeni Nesil H1 Reseptör Blokerleri

The use of New Generation H1 Receptor Blockers and Advantages in Terms of Reliability

Pages
260–268
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consequently new generationH1 receptor blockers are reliable and efficient drugs, they provide conve- nience in the treatment of allergic disorders and prevent development ofphobia against drugs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:H1 receptor blockers are one of the most commonly prescribed medicationsin the treatment of allergic disorders.
📊
Key Findings & Data:H1 receptor blockers has been usedsince 1940 and lead to some adverse effects such as sedation because oftheir chemical and pharmacological properties.
💡
Conclusion & Impact:Consequently new generationH1 receptor blockers are reliable and efficient drugs, they provide conve- nience in the treatment of allergic disorders and prevent development ofphobia against drugs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

H1 receptor blockers are one of the most commonly prescribed medicationsin the treatment of allergic disorders. These disease have reduced life qual- ity of people and prevalent in the world. H1 receptor blockers has been usedsince 1940 and lead to some adverse effects such as sedation because oftheir chemical and pharmacological properties. Therefore new generationshave been studied for reduced their adverse effect. The aims of this revieware to exhibit advantages of new produced H1 receptor blockers comparedto classical antihistamines and demonstrate efficacies of clinical uses ofnew produced H1 antihistamines. New generation H1 receptor blockerswhich have been developed after 1980s has less lipophilic properties andtheir sedative effects are minimized compared to classical antihistamines.Also, their specificity, affinity for H1 receptors and antihistaminergic effectsare higher than classical H1 receptor blockers. Although new generation H1receptor blockers are better tolerated than classical H1 receptor blockers,some of them lead to potential cardio toxicity. Consequently new generationH1 receptor blockers are reliable and efficient drugs, they provide conve- nience in the treatment of allergic disorders and prevent development ofphobia against drugs.

Özet

H1 reseptör blokerleri, toplumun genelinde yaygın görülen ve kişilerin yaşamkalitesini azaltan allerjik hastalıkların tedavisinde en sık reçete edilen ilaçlardır. 1940ların başından beri kullanılmaya başlanan klasik H1 reseptör blo- kerleri kimyasal ve farmakolojik özelliklerinden dolayı sedasyon gibi istenmeyen bazı yan etkilere neden olmaktadırlar. Bu yüzden H1 reseptör blokerlerinin yan etkileri azaltılmaya çalışılmaktadır. Bu derlemenin amacı yeni üretilenH1 reseptör blokerlerinin klasiklere göre avantajlarını ortaya koymak ve onların klinik kullanımdaki yararlarını göstermektir. 1980lerden sonra üretilmeye başlanan yeni nesil H1 reseptör blokerlerin lipofilik özellikleri azaltılmış veklasik H1 reseptör blokerlerine göre sedatif özellikleri minimuma indirilmiştir.Ayrıca yeni nesil reseptör blokerlerinin H1 reseptörlere olan spesifitesi, afinitesi ve antihistaminerjik özellikleri klasik reseptör blokerlere göre oldukçayüksektir. Yeni nesil H1 reseptör blokerleri klasiklere göre daha iyi tolere edilmesine rağmen bazıları potansiyel kardiyotoksisiteye neden olmaktadır. Sonuç olarak yeni nesil reseptör blokerleri güvenli ve etkili oldukları için allerjikhastalıkların tedavisinde kolaylık sağlamakta ve bireylerde ilaçlara karşı herhangi bir fobi gelişmesini de önlemektedir.

🔖

Cite This Article

YAYLA, M., AVŞAR, Ü. Z., CANSEVER, Z. (2022). Güvenirlik ve Kullanım Açısından Yeni Nesil H1 Reseptör Blokerleri. Journal of Clinical and Analytical Medicine, Cilt: 5 - Sayı: 3, 260–268. https://ajindex.com/articles/561149

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr 2007;85(5):1185-96
  2. Simons FE. H1-Antihistamines: more relevant than ever in the treatment of al- lergic disorders. J Allergy Clin Immunol 2003;112(4 Suppl):S42-52
  3. Camelo-Nunes IC. New antihistamines: a critical view. J Pediatr (Rio J). 2006;82(5 Suppl):S173-180. Epub 2006/12/01
  4. Jutel M, Blaser K, Akdis CA. Histamine in chronic allergic responses. J Investig Allergol Clin Immunol 2005;15(1):1-8
  5. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti- inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32(4):489-98
  6. Brunton LL. Tedavinin Farmakolojik Temeli: Goodman & Gilman Parker JSLKL, editor. İstanbul: Nobel tıp; 2008;121-6
  7. Drug Class Review: Newer Antihistamines: Final Report. Portland (OR)2006
  8. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005;65(3):341-84
  9. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147-334
  10. Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33(9):1305-24
  11. Perzanowska M, Malhotra D, Skinner SP, Rihoux JP, Bewley AP, Petersen LJ, et al. The effect of cetirizine and loratadine on codeine-induced histamine re- lease in human skin in vivo assessed by cutaneous microdialysis. Inflamm Res 1996;45(9):486-90
  12. Montoro J, Sastre J, Bartra J, del Cuvillo A, Davila I, Jauregui I, et al. Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol 2006;16 Suppl 1:24-8. 13. del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006;16 Suppl 1:3-12
  13. Ciprandi G, Catrullo A, Cerqueti P, Tosca M, Fiorino N, Canonica GW. Loratadine reduces the expression of ICAM-1. Allergy 1998;53(5):545-6
  14. Hoen PA, Bijsterbosch MK, van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats. The Journal of pharmacology and experimental therapeutics 2001;299(3):921-7
  15. Simons FE. Advances in H1-antihistamines. The New England journal of medi- cine 2004;351(21):2203-17
  16. Cuss FM. Beyond the histamine receptor: effect of